PT Metro Healthcare Indonesia Tbk

care

Overview

CARE Overview

PT Metro Healthcare Indonesia Tbk is an Indonesia-based company. The Company operates its business in an integrated health service with hospital under Metro Hospital Group. It is focused on developing technology-based health services and training centers to produce professionals in health services. The Company’s hospitals consist of mother and child hospitals and type B, type C, and type D general hospitals. The Company offers healthcare service with a range of services and facilities including polyclinic, ICU room, class III inpatient room and Super VIP room ready to cater various type of patients. The Company operates RSIA Bunda Sejahtera, RSU Bina Sehat Mandiri, RSU Metro Hospitals Cikarang, RSU Metro Hospitals Cikupa, RSU Kartini, and RSIA Santo Yusuf. Its subsidiaries include PT Metro Global Medika, PT Metro Healthcare Technologies, PT Metro Medika Abadi, PT Mitra Adika Buana, PT Indah Nusa Indonesia, PT Sejahtera Berkah Berdikari and PT Berkarya Sejahtera Gemilang.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: CARE

Development
Market Cap.
IDR 4.85Trillion

~$308.96M USD

Industry
Healthcare Providers
Sub-Industry
Healthcare Providers
Sector
Healthcare

Valuation

CARE Valuation Metrics

146

IDR

Closing Price on 2024-04-05

Price to Equity

-46.40

P/E

At -46.40x P/E TTM, CARE.JK is trading at a discount to its peers in the Healthcare Equipment & Providers sector.

Price to Book

1.56

P/B

At 1.56x P/B TTM, CARE.JK is trading in line with its peers in the Healthcare Equipment & Providers sector.

Price to Sales

22.70

P/S

At 22.70x P/S TTM, CARE.JK is trading at a premium to its peers in the Healthcare Equipment & Providers sector (avg 3.0x).

Valuing PT Metro Healthcare Indonesia Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Healthcare Equipment & Providers sector

Historical Price to Earnings

Other Valuation Metrics

Valuing PT Metro Healthcare Indonesia Tbk relative to other stocks in the Healthcare Equipment & Providers sector

Price/Cash Flow
-68.77x
Price/Forward Earnings
-
Enterprise Value/Revenue
23.59x
Enterprise Value/EBITDA
-366.60x
PEG Ratio
0.58x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of CARE stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -46.40x is below the ID market average of 8.22x and is trading at a discount to peers in the Healthcare Equipment & Providers sector (23.78x). In fact, less than 25% of its peers trade at a lower P/E ratio than CARE.●●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.56x is similar to the peers average of 1.80x in the Healthcare Equipment & Providers sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 22.70x is above the peers average of 3.00x in the Healthcare Equipment & Providers sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of CARE's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. CARE's P/CF ratio of -68.77x is considered healthy by analysts.●●
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. CARE's EV/R ratio of 23.59x is considered a relatively high ratio The average EV/R ratio for the Healthcare Equipment & Providers sector is 2.98x.
Max 3

Peers

CARE Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of CARE stock
WeightNotesScore
High
At a market cap of IDR 4,854.50 billion, CARE.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -46.40, CARE.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -24.70 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -46.40, CARE.JK is trading at a lower PE than that of its subsector peers in Healthcare Equipment & Providers (median of 23.78). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 0.21 trillion, CARE.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.10 trillion, CARE.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of CARE

Growth Forecasts

No data available

Sector Benchmark

Healthcare Equipment & Providers companies in Indonesia are growing at a projected rate of 23.68% against the IDX average of +12.0%.

Healthcare Equipment & Providers sector overview
No data is available for CARE at the moment.
Future growth prospect of CARE
WeightNotesScore
High
CARE's projected growth rate of 23.68% is above the ID market average of 11.98%.●●●
Max 3
High
The Healthcare Equipment & Providers sub-sector is projected to grow revenue by 22.97% in 2024. This number is higher than the previous year 2023's growth rate of 9.96%. This bodes well for CARE's revenue growth prospects in the next 2 years. ●●●
Max 3
Medium
The Healthcare Equipment & Providers sub-sector is projected to increase earnings by 29.75% in 2024. This number is higher than the previous year 2023's EPS growth of 9.77%. This bodes well for CARE's earnings growth prospects in the next 2 years. ●●●
Max 3
Medium
CARE and its peers in the Healthcare Equipment & Providers sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for CARE's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Ir. Henry Kembaren, Mm15.2 years
Dr. Dedi Tedjakusnadi, Mars
Director
NamePositionShares%
Bank Julius Baer And Co Ltd SingaporeDirector6,649,000,00020
Pt Metro Healthcare InternationalDirector16,599,999,99949.92
Expressed in millions IDR, unless otherwise stated

Ownership

CARE Ownership

Others
22.65%
Insiders
55.45%
Institutions
21.9%
NameNumber of SharesOwnership (%)Value
Pt Metro Healthcare International16,599,999,99949.922,423.60B
Public (Scrip)10,001,000,00130.081,460.15B
Bank Julius Baer And Co Ltd Singapore6,649,000,00020970.75B

Largest Institutional Buy

DFA Australia Limited
Bought 31-01-2024
+1,822,135 shares
BlackRock Advisors (UK) Limited
Bought 31-01-2024
+373,000 shares
BlackRock Institutional Trust Company NA
Bought 31-01-2024
+92,606 shares

Largest Institutional Sell

Fidelity Management & Research Company LLC
Sold 31-01-2024
-7,867,100 shares
Northern Trust Investments Inc
Sold 31-01-2024
-3,882,404 shares
SSGA Funds Management Inc
Sold 31-01-2024
-1,300,300 shares

Institutional Transactions

Tracking institutional transactions buying / selling of CARE stock